Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1981 1
1982 2
1983 2
1984 2
1985 2
1986 8
1987 3
1988 4
1989 5
1990 10
1991 16
1992 7
1993 25
1994 4
1995 7
1996 7
1997 12
1998 11
1999 12
2000 10
2001 13
2002 4
2003 14
2004 5
2005 15
2006 10
2007 9
2008 11
2009 13
2010 7
2011 14
2012 14
2013 10
2014 18
2015 18
2016 17
2017 19
2018 8
2019 15
2020 12
2021 12
2022 12
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Results by year

Filters applied: . Clear all
Page 1
Future Directions in the Treatment of Osteosarcoma.
Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Smrke A, et al. Cells. 2021 Jan 15;10(1):172. doi: 10.3390/cells10010172. Cells. 2021. PMID: 33467756 Free PMC article. Review.
Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. ...Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune th …
Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is stro …
HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, Liu Y, Ke X, Guo S, Guo Z. Xiao X, et al. J Exp Clin Cancer Res. 2018 Aug 28;37(1):201. doi: 10.1186/s13046-018-0880-6. J Exp Clin Cancer Res. 2018. PMID: 30153855 Free PMC article.
BACKGROUND: Osteosarcoma is the most common primary bone tumor in children and adolescents. ...TUNEL and LC3 staining were performed to detect apoptosis and autophagy of resected tumor tissues. RESULTS: Doxorubicin, cisplatin, and methotrexate, which are comm …
BACKGROUND: Osteosarcoma is the most common primary bone tumor in children and adolescents. ...TUNEL and LC3 staining were performed …
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Smeland S, et al. Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25. Eur J Cancer. 2019. PMID: 30685685 Free PMC article. Clinical Trial.
The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials. ...In radically operated patients, there was no good evidence that axial tu …
The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this r …
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M; EURAMOS collaborators. Whelan JS, et al. Ann Oncol. 2015 Feb;26(2):407-14. doi: 10.1093/annonc/mdu526. Epub 2014 Nov 24. Ann Oncol. 2015. PMID: 25421877 Free PMC article. Clinical Trial.
BACKGROUND: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. PATIENTS AND …
BACKGROUND: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised …
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. PATIE …
PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon a …
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.
Erdoğan F, Çinka H, Akman BÇ, Coşkun HS, Dabak N. Erdoğan F, et al. Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14. Jt Dis Relat Surg. 2023. PMID: 36700283 Free PMC article.
OBJECTIVES: This study aims to examine the clinical results of patients who underwent medical and surgical treatment for osteosarcoma, to determine the overall survival (OS) and disease-free survival (DFS) rates, and to examine the effects of prognostic factors on t …
OBJECTIVES: This study aims to examine the clinical results of patients who underwent medical and surgical treatment for osteosarc …
Metastatic osteosarcoma.
Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH. Daw NC, et al. Cancer. 2006 Jan 15;106(2):403-12. doi: 10.1002/cncr.21626. Cancer. 2006. PMID: 16353204 Free article. Clinical Trial.
The initial study (OS-86) used ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate, and the subsequent study (OS-91) used the same agents at similar doses, but carboplatin was substituted for cisplatin. ...Unilateral lung metastases (P = 0.006), no …
The initial study (OS-86) used ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate, and the subsequent study (OS-91 …
An update on chemotherapy for osteosarcoma.
Ferrari S, Serra M. Ferrari S, et al. Expert Opin Pharmacother. 2015;16(18):2727-36. doi: 10.1517/14656566.2015.1102226. Epub 2015 Oct 29. Expert Opin Pharmacother. 2015. PMID: 26512909 Review.
INTRODUCTION: In the early seventies chemotherapy significantly improved survival in osteosarcoma. Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance. ...The MAP (methotrexate, doxorubicin …
INTRODUCTION: In the early seventies chemotherapy significantly improved survival in osteosarcoma. Since then minor innovations have …
Establishment and Characterization of Single and Triple-Agent Resistant Osteosarcoma Cell Lines.
Low K, Hills F, Roberts HC, Stordal B. Low K, et al. Adv Biol (Weinh). 2023 Feb;7(2):e2200194. doi: 10.1002/adbi.202200194. Epub 2022 Dec 8. Adv Biol (Weinh). 2023. PMID: 36480329
Cisplatin, doxorubicin, and methotrexate are used as single agents and in triple combination. ...Apoptosis assays suggest that the resistance in MG-63/TRIR8 isfrom cisplatin and methotrexate and not doxorubicin. In contrast, the resistance in HOS-143B/ …
Cisplatin, doxorubicin, and methotrexate are used as single agents and in triple combination. ...Apoptosis assays suggest that …
Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
Yang YT, Yuzbasiyan-Gurkan V. Yang YT, et al. Int J Mol Sci. 2022 Aug 19;23(16):9345. doi: 10.3390/ijms23169345. Int J Mol Sci. 2022. PMID: 36012610 Free PMC article.
Our data point to synergistic effects when sorafenib is combined with doxorubicin, but not when combined with cisplatin or carboplatin, in both human and canine OSA. Based on current findings, clinical trials using a combination of doxorubicin and sora …
Our data point to synergistic effects when sorafenib is combined with doxorubicin, but not when combined with cisplatin or car …
404 results